Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations. Presentations are scheduled at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT and the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. Investors may request one-on-one meetings through their Leerink, ROTH, or NAHC representative.
Ligand (Nasdaq: LGND) reported strong fourth-quarter and full-year 2025 results with total revenues of $59.7M (Q4) and $268.1M (2025). Full-year royalty revenue grew 48%, to $161.0M. GAAP net income was $124.5M for 2025; core adjusted net income was $165.1M or $8.13 per diluted share. The company reaffirmed 2026 guidance: $245M–$285M revenue and adjusted EPS of $8.00–$9.00. Cash, cash equivalents and short-term investments totaled $733.5M as of December 31, 2025.
Key commercial and clinical updates include regulatory filings, positive Phase 3/2 readouts across partnered programs, and recent transactions affecting contract revenue and royalties.
Ligand (Nasdaq: LGND) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, and will host a conference call at 8:30 a.m. ET with live webcast and replay available.
The company described its asset-light royalty and technology licensing model, highlighted Captisol and NITRICIL platforms, and urged investors to monitor its investor relations website and X for material disclosures.
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Management is also scheduled for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.
Ligand (Nasdaq: LGND) hosted an Investor Day on Dec 9, 2025 and introduced 2026 guidance. The company forecasted 2026 total revenue $245m–$285m, including royalty revenue $200m–$225m (about a 40% increase vs 2025) and core adjusted EPS $8.00–$9.00. Ligand reiterated 2025 guidance of core revenue $225m–$235m and outlined a 5-year royalty receipts outlook of ≥23% CAGR. Management highlighted drivers including Filspari, Ohtuvayre, Capvaxive, Qarziba, and Zelsuvmi, noted $1 billion of deployable capital for royalty investments, and described Captisol and NITRICIL as royalty-generating platforms. The Investor Day was webcast live with presentation replay available on the company website.
Ligand (Nasdaq: LGND) reported Q3 2025 revenue $115.5M (up 123% YoY) and raised 2025 core revenue guidance to $225M–$235M and core adjusted EPS to $7.40–$7.65. Q3 royalties were $46.6M (up 47% YoY). GAAP net income was $117.3M or $5.68 per diluted share; adjusted net income was $63.8M or $3.09 per diluted share. Cash, cash equivalents and short-term investments totaled $664.5M as of Sept 30, 2025. Company completed a $460M 2030 convertible notes offering (net proceeds ~$445M) and recognized a $28.6M gain from the Pelthos sale and $24.5M from a Zelsuvmi out-license.
Ligand (Nasdaq: LGND) announced CEO Todd Davis and CFO Tavo Espinoza will attend three investor conferences in November 2025.
Key dates: UBS Global Healthcare Conference one-on-one meetings on November 10, 2025; Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 8:40 a.m. ET; Southwest IDEAS 2025 Investor Conference presentation on November 20, 2025 at 1:20 p.m. CT. Management will host one-on-one investor meetings; investors should contact their UBS or Stifel representative to arrange meetings.
Ligand (Nasdaq: LGND) will report third quarter 2025 financial results on Thursday, November 6, 2025. A conference call will begin at 8:30 AM Eastern Time to discuss results and provide a business update.
Investors can join by phone in the U.S. and Canada at (800) 715-9871 or internationally at (646) 307-1963 using Conference ID 3661098. A live webcast and replay will be available via the company webcast link.
Ligand (Nasdaq: LGND) will hold its annual Investor Day on December 9, 2025 in New York City at The Harvard Club from 10:30 a.m. to 12:00 p.m. ET. Management presentations will include CEO Todd Davis and CFO Tavo Espinoza and will cover the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook.
Guest speaker Scott Plesha, CEO of partner Pelthos Therapeutics, will discuss the recent launch of ZELSUVMI (berdazimer) topical gel 10.3%, described as the first FDA-approved at-home treatment for molluscum contagiosum. A live webcast and replay will be available on Ligand’s investor relations website, and investors can register for the event online.
Ligand (Nasdaq: LGND) said partner SQ Innovation received FDA approval on October 9, 2025 for Lasix ONYU (furosemide injection), a drug‑device combo enabling subcutaneous, at‑home treatment of edema in adults with chronic heart failure.
Lasix ONYU is a high‑concentration furosemide formulation (80mg/2.67mL; 30mg/mL) using Captisol and pairs with a reusable Infusor (48 treatments) plus a sterile single‑use cartridge. Captisol is cited as a key enabler and this is the 17th Captisol‑enabled product. Ligand holds exclusive Captisol license/supply terms with SQ Innovation signed in 2019 and will receive milestone payments, a low‑single‑digit royalty, and material sales revenue. SQ Innovation expects product availability in Q4 2025.